Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 43

  • The following terms were not found in PubMed: csg452[ti], deberza[ti], apleway[ti].
1.

Rationale and Design of the STOP-OB Study for Evaluating the Effects of Tofogliflozin and Glimepiride on Fat Deposition in Type 2 Diabetes Patients Treated with Metformin/DPP-4 Inhibitor Dual Therapy.

Ishihara H, Anai M, Seino H, Kitazawa T, Ohashi H, Ai M, Inoue M, Fujishiro M, Inazawa T, Kuroda H, Yamada M.

Diabetes Ther. 2018 Aug 25. doi: 10.1007/s13300-018-0491-4. [Epub ahead of print]

PMID:
30145651
2.

Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Tofogliflozin (A SELECTIVE SGLT2 Inhibitor) in Patients with Type 2 Diabetes Mellitus.

Ikeda S, Takano Y, Schwab D, Portron A, Kasahara-Ito N, Saito T, Iida S.

Drug Res (Stuttg). 2018 Aug 13. doi: 10.1055/a-0662-0209. [Epub ahead of print]

PMID:
30103216
3.

Switching dipeptidyl peptidase-4 inhibitors to tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2 improves arterial stiffness evaluated by cardio-ankle vascular index in patients with type 2 diabetes: a pilot study

Bekki M, Tahara N, Tahara A, Igata S, Honda A, Sugiyama Y, Nakamura T, Sun J, Kumashiro Y, Matsui T, Fukumoto Y, Yamagishi S-I.

Curr Vasc Pharmacol. 2018 May 15. doi: 10.2174/1570161116666180515154555. [Epub ahead of print]

PMID:
29766812
4.

This is in reply to the Letter by Kahathuduwa et al. titled "Unaccounted for regression to the mean renders conclusion of article titled 'Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor Tofogliflozin' unsubstantiated".

Ouchi M, Oba K, Suganami H, Yoshida A, Fujita T, Suzuki T, Yasutake M, Kaku K.

Diabetes Obes Metab. 2018 Aug;20(8):2041-2042. doi: 10.1111/dom.13347. Epub 2018 Jun 5. No abstract available.

PMID:
29749099
5.

Unaccounted for regression to the mean renders conclusion of article titled "Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor tofogliflozin" unsubstantiated.

Kahathuduwa CN, Thomas DM, Siu C, Allison DB.

Diabetes Obes Metab. 2018 Aug;20(8):2039-2040. doi: 10.1111/dom.13323. Epub 2018 May 3. No abstract available.

PMID:
29660244
6.

Metabolic effects of Tofogliflozin are efficiently enhanced with appropriate dietary carbohydrate ratio and are distinct from carbohydrate restriction.

Ito S, Hosaka T, Yano W, Itou T, Yasumura M, Shimizu Y, Kobayashi H, Nakagawa T, Inoue K, Tanabe S, Kondo T, Ishida H.

Physiol Rep. 2018 Mar;6(5). doi: 10.14814/phy2.13642.

7.

Effect of Tofogliflozin on Body Composition and Glycemic Control in Japanese Subjects with Type 2 Diabetes Mellitus.

Kamei S, Iwamoto M, Kameyama M, Shimoda M, Kinoshita T, Obata A, Kimura T, Hirukawa H, Tatsumi F, Kohara K, Nakanishi S, Mune T, Kaku K, Kaneto H.

J Diabetes Res. 2018 Jan 8;2018:6470137. doi: 10.1155/2018/6470137. eCollection 2018.

8.
9.

Tofogliflozin decreases body fat mass and improves peripheral insulin resistance.

Matsuba R, Matsuba I, Shimokawa M, Nagai Y, Tanaka Y.

Diabetes Obes Metab. 2018 May;20(5):1311-1315. doi: 10.1111/dom.13211. Epub 2018 Feb 4.

10.

Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor tofogliflozin.

Ouchi M, Oba K, Kaku K, Suganami H, Yoshida A, Fukunaka Y, Jutabha P, Morita A, Otani N, Hayashi K, Fujita T, Suzuki T, Yasutake M, Anzai N.

Diabetes Obes Metab. 2018 Apr;20(4):1061-1065. doi: 10.1111/dom.13170. Epub 2018 Jan 8.

11.
12.

Preventive effects of the sodium glucose cotransporter 2 inhibitor tofogliflozin on diethylnitrosamine-induced liver tumorigenesis in obese and diabetic mice.

Obara K, Shirakami Y, Maruta A, Ideta T, Miyazaki T, Kochi T, Sakai H, Tanaka T, Seishima M, Shimizu M.

Oncotarget. 2017 Apr 6;8(35):58353-58363. doi: 10.18632/oncotarget.16874. eCollection 2017 Aug 29.

13.

Comparison of tofogliflozin 20 mg and ipragliflozin 50 mg used together with insulin glargine 300 U/mL using continuous glucose monitoring (CGM): A randomized crossover study.

Takeishi S, Tsuboi H, Takekoshi S.

Endocr J. 2017 Oct 28;64(10):995-1005. doi: 10.1507/endocrj.EJ17-0206. Epub 2017 Aug 18.

14.

Pharmacokinetics and Pharmacodynamics of Tofogliflozin (a Selective SGLT2 Inhibitor) in Healthy Male Subjects.

Kasahara-Ito N, Fukase H, Ogama Y, Saito T, Ohba Y, Shimada S, Takano Y, Ichihara T, Terao K, Nakamichi N, Kumagai Y, Ikeda S.

Drug Res (Stuttg). 2017 Jun;67(6):349-357. doi: 10.1055/s-0043-104779. Epub 2017 Apr 20.

PMID:
28427104
15.

The Effect of Tofogliflozin Treatment on Postprandial Glucose and Lipid Metabolism in Japanese Men With Type 2 Diabetes: A Pilot Study.

Kakuda H, Kobayashi J, Sakurai M, Kakuda M, Takekoshi N.

J Clin Med Res. 2017 May;9(5):403-409. doi: 10.14740/jocmr2806w. Epub 2017 Apr 1.

17.

Safety and effectiveness of tofogliflozin in elderly Japanese patients with type 2 diabetes mellitus: A post-marketing study (J-STEP/EL Study).

Utsunomiya K, Shimmoto N, Senda M, Kurihara Y, Gunji R, Fujii S, Kakiuchi S, Fujiwara H, Kameda H, Tamura M, Kaku K.

J Diabetes Investig. 2017 Nov;8(6):766-775. doi: 10.1111/jdi.12626. Epub 2017 Mar 6.

18.

Impact of the 8-week Administration of Tofogliflozin for Glycemic Control and Body Composition in Japanese Patients with Type 2 Diabetes Mellitus.

Hirose S, Nakajima S, Iwahashi Y, Seo A, Takahashi T, Tamori Y.

Intern Med. 2016;55(22):3239-3245. Epub 2016 Nov 15.

19.

Pharmacological analysis of SGLT2 inhibitor (tofogliflozin) using in vivo glucose clamp and titration protocols in rats and cynomolgus monkeys.

Fukazawa M, Nagata T, Suzuki M, Suzuki Y, Kawabe Y.

Nihon Yakurigaku Zasshi. 2016;148(5):259-265. doi: 10.1254/fpj.148.259. Japanese. No abstract available.

PMID:
27803439
20.

Supplemental Content

Loading ...
Support Center